Neuroendocrine tumors: Insights into innovative therapeutic options and rational development of targeted therapies

Federica Barbieri, Manuela Albertelli, Federica Grillo, Amira Mohamed, Alexandru Saveanu, Anne Barlier, Diego Ferone, Tullio Florio

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Neuroendocrine tumors (NETs) are heterogeneous neoplasms with respect to molecular characteristics and clinical outcome. Although slow-growing, NETs are often late diagnosed, already showing invasion of adjacent tissues and metastases. Precise knowledge of NET biological and molecular features has opened the door to the identification of novel pharmacological targets. Therapeutic options include somatostatin analogs, alone or in combination with interferon-α, multi-targeted tyrosine kinase inhibitors (e.g. sunitinib) or mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus). Antiangiogenic approaches and anti insulin-like growth factor receptor (IGFR) compounds have been also proposed as combination therapies with the aforementioned compounds. This review will focus on recent studies that have improved therapeutic strategies in NETs, discussing management challenges such as drug resistance development as well as focusing on the need for predictive biomarkers to design distinct drug combinations and optimize pharmacological control.

Original languageEnglish
Pages (from-to)458-468
Number of pages11
JournalDrug Discovery Today
Volume19
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Neuroendocrine Tumors
Pharmacology
Somatomedin Receptors
Drug Combinations
Sirolimus
Therapeutics
Somatostatin
Drug Resistance
Protein-Tyrosine Kinases
Interferons
Biomarkers
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Neuroendocrine tumors : Insights into innovative therapeutic options and rational development of targeted therapies. / Barbieri, Federica; Albertelli, Manuela; Grillo, Federica; Mohamed, Amira; Saveanu, Alexandru; Barlier, Anne; Ferone, Diego; Florio, Tullio.

In: Drug Discovery Today, Vol. 19, No. 4, 2014, p. 458-468.

Research output: Contribution to journalArticle

Barbieri, Federica ; Albertelli, Manuela ; Grillo, Federica ; Mohamed, Amira ; Saveanu, Alexandru ; Barlier, Anne ; Ferone, Diego ; Florio, Tullio. / Neuroendocrine tumors : Insights into innovative therapeutic options and rational development of targeted therapies. In: Drug Discovery Today. 2014 ; Vol. 19, No. 4. pp. 458-468.
@article{a62bcd65dd584b09b30d34687b1c85da,
title = "Neuroendocrine tumors: Insights into innovative therapeutic options and rational development of targeted therapies",
abstract = "Neuroendocrine tumors (NETs) are heterogeneous neoplasms with respect to molecular characteristics and clinical outcome. Although slow-growing, NETs are often late diagnosed, already showing invasion of adjacent tissues and metastases. Precise knowledge of NET biological and molecular features has opened the door to the identification of novel pharmacological targets. Therapeutic options include somatostatin analogs, alone or in combination with interferon-α, multi-targeted tyrosine kinase inhibitors (e.g. sunitinib) or mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus). Antiangiogenic approaches and anti insulin-like growth factor receptor (IGFR) compounds have been also proposed as combination therapies with the aforementioned compounds. This review will focus on recent studies that have improved therapeutic strategies in NETs, discussing management challenges such as drug resistance development as well as focusing on the need for predictive biomarkers to design distinct drug combinations and optimize pharmacological control.",
author = "Federica Barbieri and Manuela Albertelli and Federica Grillo and Amira Mohamed and Alexandru Saveanu and Anne Barlier and Diego Ferone and Tullio Florio",
year = "2014",
doi = "10.1016/j.drudis.2013.10.015",
language = "English",
volume = "19",
pages = "458--468",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Neuroendocrine tumors

T2 - Insights into innovative therapeutic options and rational development of targeted therapies

AU - Barbieri, Federica

AU - Albertelli, Manuela

AU - Grillo, Federica

AU - Mohamed, Amira

AU - Saveanu, Alexandru

AU - Barlier, Anne

AU - Ferone, Diego

AU - Florio, Tullio

PY - 2014

Y1 - 2014

N2 - Neuroendocrine tumors (NETs) are heterogeneous neoplasms with respect to molecular characteristics and clinical outcome. Although slow-growing, NETs are often late diagnosed, already showing invasion of adjacent tissues and metastases. Precise knowledge of NET biological and molecular features has opened the door to the identification of novel pharmacological targets. Therapeutic options include somatostatin analogs, alone or in combination with interferon-α, multi-targeted tyrosine kinase inhibitors (e.g. sunitinib) or mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus). Antiangiogenic approaches and anti insulin-like growth factor receptor (IGFR) compounds have been also proposed as combination therapies with the aforementioned compounds. This review will focus on recent studies that have improved therapeutic strategies in NETs, discussing management challenges such as drug resistance development as well as focusing on the need for predictive biomarkers to design distinct drug combinations and optimize pharmacological control.

AB - Neuroendocrine tumors (NETs) are heterogeneous neoplasms with respect to molecular characteristics and clinical outcome. Although slow-growing, NETs are often late diagnosed, already showing invasion of adjacent tissues and metastases. Precise knowledge of NET biological and molecular features has opened the door to the identification of novel pharmacological targets. Therapeutic options include somatostatin analogs, alone or in combination with interferon-α, multi-targeted tyrosine kinase inhibitors (e.g. sunitinib) or mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus). Antiangiogenic approaches and anti insulin-like growth factor receptor (IGFR) compounds have been also proposed as combination therapies with the aforementioned compounds. This review will focus on recent studies that have improved therapeutic strategies in NETs, discussing management challenges such as drug resistance development as well as focusing on the need for predictive biomarkers to design distinct drug combinations and optimize pharmacological control.

UR - http://www.scopus.com/inward/record.url?scp=84899535126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899535126&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2013.10.015

DO - 10.1016/j.drudis.2013.10.015

M3 - Article

C2 - 24171952

AN - SCOPUS:84899535126

VL - 19

SP - 458

EP - 468

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 4

ER -